Introduction Accumulated high-quality data from randomised controlled trials (RCTs)
indicate that long-acting muscarinic antagonist (LAMA)/long-acting β2 agonist (LABA) …

Objective Long-acting β2-agonists (LABAs) and long-acting muscarinic antagonists (LAMAs)
are burdened by the potential risk of inducing cardiovascular serious adverse events (SAEs) …

The cardiovascular risk of concurrently using long-acting β2-agonists (LABAs) and
anticholinergics (LAMAs) in COPD is uncertain. We assessed the comparative …

Long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist (LABA) bronchodilators
and their combination are recommended for the maintenance treatment of chronic …

Background: The recent approval of several fixed-dose combination long-acting β2-agonist
(LABA) and long-acting muscarinic antagonist (LAMA) products has increased the use of …

Introduction We performed a real-life retrospective analysis to assess the impact of long-
acting bronchodilator therapy and associated exposure to inhaled corticosteroids (ICS) on …

A majority of existing studies have focused on the efficacy of inhaled long-acting
bronchodilators (ILABs), such as long-acting muscarinic antagonists (LAMAs) and long …

Because there is a solid pharmacological rationale based on positive interactions between
long‐acting muscarinic receptor antagonists (LAMAs) and long‐acting β‐agonists (LABAs) …

Background: Long-acting muscarinic antagonist (LAMA) monotherapy is recommended for
chronic obstructive pulmonary disease (COPD) patients with high risk of exacerbations. It is …

Combining a long-acting β 2-agonist (LABA) with a long-acting anti-muscarinic agent
(LAMA) provides synergistic benefit on airway smooth muscle relaxation, which may have …